FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2623834878> ?p ?o ?g. }

• W2623834878 endingPage "130" @default.
• W2623834878 startingPage "123" @default.
• W2623834878 abstract "Although infliximab (IFX) is an efficient therapy for ulcerative colitis (UC) patients, a considerably high rate of therapeutic failures still occurs. This study aimed at a better understanding of IFX pharmacokinetics and pharmacodynamics among clinically-asymptomatic UC patients. This was a multicentric and prospective study involving 65 UC patients in the maintenance phase of IFX therapy. There were no significant differences between patients with positive and negative clinical, endoscopic and histological outcomes concerning their IFX trough levels (TLs), area under the IFX concentration vs. time curve (AUC), clearance and antibodies to infliximab (ATI) levels. However, the need to undergo therapeutic escalation later in disease development was significantly associated with higher ATI levels (2.62 μg/mL vs. 1.15 μg/mL, p = 0.028). Moreover, and after adjusting for disease severity, the HR (hazard ratio) for therapeutic escalation was significantly decreased for patients with an ATI concentration below 3 μg/mL (HR = 0.119, p = 0.010), and increased for patients with fecal calprotectin (FC) level above 250 μg/g (HR = 9.309, p = 0.018). In clinically-stable UC patients, IFX pharmacokinetic features cannot predict therapeutic response on a short-term basis. However, high levels of ATIs or FC may be indicative of a future therapeutic escalation." @default.
• W2623834878 created "2017-06-15" @default.
• W2623834878 creator A5000574019 @default.
• W2623834878 creator A5005703800 @default.
• W2623834878 creator A5020006756 @default.
• W2623834878 creator A5024379528 @default.
• W2623834878 creator A5024495842 @default.
• W2623834878 creator A5025345424 @default.
• W2623834878 creator A5026242093 @default.
• W2623834878 creator A5026490001 @default.
• W2623834878 creator A5039453385 @default.
• W2623834878 creator A5041950395 @default.
• W2623834878 creator A5044736243 @default.
• W2623834878 creator A5045954380 @default.
• W2623834878 creator A5048397826 @default.
• W2623834878 creator A5052535018 @default.
• W2623834878 creator A5056740989 @default.
• W2623834878 creator A5062264742 @default.
• W2623834878 creator A5065988619 @default.
• W2623834878 creator A5070698030 @default.
• W2623834878 creator A5073507471 @default.
• W2623834878 creator A5079391373 @default.
• W2623834878 creator A5083341377 @default.
• W2623834878 creator A5084134209 @default.
• W2623834878 creator A5090361086 @default.
• W2623834878 creator A5090684429 @default.
• W2623834878 date "2017-07-01" @default.
• W2623834878 modified "2023-10-16" @default.
• W2623834878 title "Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation" @default.
• W2623834878 cites W1990311132 @default.
• W2623834878 cites W1998966252 @default.
• W2623834878 cites W2003835888 @default.
• W2623834878 cites W2027190512 @default.
• W2623834878 cites W2044160586 @default.
• W2623834878 cites W2050154180 @default.
• W2623834878 cites W2070306841 @default.
• W2623834878 cites W2071538770 @default.
• W2623834878 cites W2088135039 @default.
• W2623834878 cites W2102245241 @default.
• W2623834878 cites W2106072130 @default.
• W2623834878 cites W2114266978 @default.
• W2623834878 cites W2116318925 @default.
• W2623834878 cites W2126568228 @default.
• W2623834878 cites W2134803931 @default.
• W2623834878 cites W2135328294 @default.
• W2623834878 cites W2190276498 @default.
• W2623834878 cites W2198790708 @default.
• W2623834878 cites W2244428638 @default.
• W2623834878 cites W2269814466 @default.
• W2623834878 cites W2275273416 @default.
• W2623834878 cites W2321205867 @default.
• W2623834878 cites W2338711718 @default.
• W2623834878 cites W2400356130 @default.
• W2623834878 cites W2486917331 @default.
• W2623834878 cites W2507611985 @default.
• W2623834878 cites W2513920879 @default.
• W2623834878 cites W2530199480 @default.
• W2623834878 doi "https://doi.org/10.1016/j.ebiom.2017.06.004" @default.
• W2623834878 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5514398" @default.
• W2623834878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28629912" @default.
• W2623834878 hasPublicationYear "2017" @default.
• W2623834878 type Work @default.
• W2623834878 sameAs 2623834878 @default.
• W2623834878 citedByCount "8" @default.
• W2623834878 countsByYear W26238348782018 @default.
• W2623834878 countsByYear W26238348782019 @default.
• W2623834878 countsByYear W26238348782020 @default.
• W2623834878 countsByYear W26238348782021 @default.
• W2623834878 countsByYear W26238348782023 @default.
• W2623834878 crossrefType "journal-article" @default.
• W2623834878 hasAuthorship W2623834878A5000574019 @default.
• W2623834878 hasAuthorship W2623834878A5005703800 @default.
• W2623834878 hasAuthorship W2623834878A5020006756 @default.
• W2623834878 hasAuthorship W2623834878A5024379528 @default.
• W2623834878 hasAuthorship W2623834878A5024495842 @default.
• W2623834878 hasAuthorship W2623834878A5025345424 @default.
• W2623834878 hasAuthorship W2623834878A5026242093 @default.
• W2623834878 hasAuthorship W2623834878A5026490001 @default.
• W2623834878 hasAuthorship W2623834878A5039453385 @default.
• W2623834878 hasAuthorship W2623834878A5041950395 @default.
• W2623834878 hasAuthorship W2623834878A5044736243 @default.
• W2623834878 hasAuthorship W2623834878A5045954380 @default.
• W2623834878 hasAuthorship W2623834878A5048397826 @default.
• W2623834878 hasAuthorship W2623834878A5052535018 @default.
• W2623834878 hasAuthorship W2623834878A5056740989 @default.
• W2623834878 hasAuthorship W2623834878A5062264742 @default.
• W2623834878 hasAuthorship W2623834878A5065988619 @default.
• W2623834878 hasAuthorship W2623834878A5070698030 @default.
• W2623834878 hasAuthorship W2623834878A5073507471 @default.
• W2623834878 hasAuthorship W2623834878A5079391373 @default.
• W2623834878 hasAuthorship W2623834878A5083341377 @default.
• W2623834878 hasAuthorship W2623834878A5084134209 @default.
• W2623834878 hasAuthorship W2623834878A5090361086 @default.
• W2623834878 hasAuthorship W2623834878A5090684429 @default.
• W2623834878 hasBestOaLocation W26238348781 @default.
• W2623834878 hasConcept C111113717 @default.
• W2623834878 hasConcept C112705442 @default.
• W2623834878 hasConcept C126322002 @default.

• next